GET Stock QuotesNews18 APP
News18 English
»
1-min read

British Drug-maker, Indivior, Shares Rise After US Court Blocks Dr.Reddy's Rival Generic Drug

Dr Reddy's, though, has said it would launch its new drug regardless of the legal squabble.

Reuters

Updated:June 18, 2018, 2:44 PM IST
facebookTwittergoogleskypewhatsapp
British Drug-maker, Indivior, Shares Rise After US Court Blocks Dr.Reddy's Rival Generic Drug
Representative Image
Loading...
London: Shares in British drugmaker Indivior rose on Monday after a US Court granted a temporary restraining order blocking Dr. Reddy's Laboratories from launching a generic version of Indivior's best-selling opioid addiction treatment.

Indivior shares rose more than 6 percent in early trade, after falling by nearly a third on Friday after Dr Reddy's and US-based Mylan NV received FDA approval for a generic version of Suboxone Film, which generates 80 percent of Indivior's revenue.

Indivior said on Saturday that the US District Court for the District of New Jersey granted it a temporary restraining order, which will remain in place pending a hearing on the preliminary injunction motion filed by Indivior on Friday.

"We are pleased that the Court has granted our request for a temporary restraining order. We will continue to pursue all legal avenues against Dr. Reddy's to protect our Suboxone Film patent," Indivior Chief Executive Shaun Thaxter said.

A hearing on the preliminary injunction motion has been scheduled for June 28, and the company will seek to extend the cessation of launch activities by Dr. Reddy's pending the outcome of the recently filed litigation against Dr Reddy's.

Dr Reddy's said on Friday it would launch its new drug regardless of the legal squabble.

Generic rivals in tablet form are already on the US market, which is grappling with an opioid addiction epidemic that killed 33,000 people in 2015, but Suboxone Film leads the market with its version which is placed under the tongue to suppress cravings.

Indivior stuck to its 2018 revenue guidance on Friday but said it would revisit the forecast if Dr. Reddy's launches the cheaper drug.

It said Dr. Reddy's launch could 'potentially result in a rapid and material loss of market share for the drug in the US, an effect that could occur within months of a successful launch of a generic film alternative.'

Indivior also said it was considering a potential launch of its own generic and operational cost cuts in response. It said its contingency plans would also focus on optimising the launch of Sublocade, a once-a-month injectable drug to suppress opioid craving that it launched in the United States in February.​


Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwittergoogleskypewhatsapp
Most Active
Company Price Change %Gain
Yes Bank 226.50 -92.70 -29.04
Dewan Housing 350.55 -260.00 -42.58
Reliance 1,217.50 +6.75 +0.56
Axis Bank 599.20 -9.60 -1.58
Tata Steel 625.15 +3.95 +0.64
Company Price Change %Gain
Dewan Housing 351.55 -259.05 -42.43
Yes Bank 227.05 -91.45 -28.71
Maruti Suzuki 8,039.55 -167.45 -2.04
Indiabulls Hsg 1,061.90 -94.60 -8.18
Oracle Fin Serv 4,031.30 -71.85 -1.75
Top Gainers
Company Price Change %Gain
Bharti Infratel 281.20 +10.30 +3.80
BPCL 376.50 +11.45 +3.14
IOC 158.15 +4.60 +3.00
HPCL 258.00 +6.65 +2.65
Hindalco 240.40 +4.75 +2.02
Company Price Change %Gain
ONGC 180.10 +3.45 +1.95
Wipro 337.35 +4.60 +1.38
ITC 303.75 +4.10 +1.37
TCS 2,103.80 +26.90 +1.30
Asian Paints 1,303.10 +13.75 +1.07
Top Losers
Company Price Change %Gain
Yes Bank 226.50 -92.70 -29.04
Indiabulls Hsg 1,062.15 -97.10 -8.38
Bajaj Finance 2,379.40 -120.15 -4.81
Tech Mahindra 738.05 -31.90 -4.14
UPL 665.80 -26.50 -3.83
Company Price Change %Gain
Yes Bank 227.05 -91.45 -28.71
Kotak Mahindra 1,179.65 -47.35 -3.86
Adani Ports 362.00 -10.95 -2.94
IndusInd Bank 1,761.70 -42.90 -2.38
Maruti Suzuki 8,039.55 -167.45 -2.04

Live TV

Loading...
Loading...